TScan Therapeutics (TCRX) Competitors $1.79 +0.07 (+4.07%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.76 -0.03 (-1.62%) As of 09/19/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRX vs. SLDB, ATXS, NBTX, FULC, CGEM, KMDA, INBX, AURA, ADCT, and PRTCShould you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Nanobiotix (NBTX), Fulcrum Therapeutics (FULC), Cullinan Therapeutics (CGEM), Kamada (KMDA), Inhibrx Biosciences (INBX), Aura Biosciences (AURA), ADC Therapeutics (ADCT), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry. TScan Therapeutics vs. Its Competitors Solid Biosciences Astria Therapeutics Nanobiotix Fulcrum Therapeutics Cullinan Therapeutics Kamada Inhibrx Biosciences Aura Biosciences ADC Therapeutics PureTech Health TScan Therapeutics (NASDAQ:TCRX) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Do institutionals & insiders have more ownership in TCRX or SLDB? 82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 4.4% of TScan Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, TCRX or SLDB? Solid Biosciences has higher revenue and earnings than TScan Therapeutics. Solid Biosciences is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTScan Therapeutics$2.82M36.02-$127.50M-$1.09-1.64Solid Biosciences$8.09M49.28-$124.70M-$2.80-1.83 Do analysts recommend TCRX or SLDB? TScan Therapeutics currently has a consensus target price of $7.80, indicating a potential upside of 335.75%. Solid Biosciences has a consensus target price of $15.00, indicating a potential upside of 192.97%. Given TScan Therapeutics' higher possible upside, equities analysts clearly believe TScan Therapeutics is more favorable than Solid Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Which has more volatility & risk, TCRX or SLDB? TScan Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Solid Biosciences has a beta of 2.54, meaning that its stock price is 154% more volatile than the S&P 500. Does the media prefer TCRX or SLDB? In the previous week, Solid Biosciences had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 2 mentions for Solid Biosciences and 1 mentions for TScan Therapeutics. Solid Biosciences' average media sentiment score of 0.75 beat TScan Therapeutics' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solid Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TCRX or SLDB more profitable? Solid Biosciences has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,964.88%. TScan Therapeutics' return on equity of -63.33% beat Solid Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets TScan Therapeutics-1,964.88% -63.33% -40.19% Solid Biosciences N/A -69.70%-56.74% SummarySolid Biosciences beats TScan Therapeutics on 10 of the 17 factors compared between the two stocks. Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRX vs. The Competition Export to ExcelMetricTScan TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.61M$3.15B$5.79B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio-1.6421.0580.5026.78Price / Sales36.02448.41534.22123.54Price / CashN/A46.6037.9961.55Price / Book0.429.6615.776.40Net Income-$127.50M-$53.22M$3.30B$271.80M7 Day Performance1.70%3.11%5.36%3.48%1 Month Performance5.29%7.56%8.09%9.90%1 Year Performance-67.57%11.15%81.36%28.44% TScan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRXTScan Therapeutics2.5637 of 5 stars$1.79+4.1%$7.80+335.8%-68.3%$97.61M$2.82M-1.64100Positive NewsSLDBSolid Biosciences2.7085 of 5 stars$5.13-6.7%$15.00+192.4%-36.0%$428.28M$8.09M-1.83100ATXSAstria Therapeutics3.0914 of 5 stars$7.43-1.2%$29.00+290.3%-42.9%$424.39MN/A-3.7030News CoveragePositive NewsAnalyst ForecastNBTXNanobiotix0.7727 of 5 stars$8.71+0.1%$8.00-8.2%+117.5%$417.11M$39.18M0.00100Trending NewsUpcoming EarningsAnalyst ForecastShort Interest ↑FULCFulcrum Therapeutics2.5623 of 5 stars$7.27-5.1%$7.57+4.1%+114.2%$414.34M$80M-5.96100CGEMCullinan Therapeutics2.3537 of 5 stars$6.84-2.1%$26.80+291.8%-65.4%$412.93MN/A-2.1230Positive NewsAnalyst UpgradeKMDAKamada4.4696 of 5 stars$7.22+1.1%$13.00+80.1%+26.8%$410.59M$169.52M21.24360Positive NewsShort Interest ↓INBXInhibrx Biosciences1.1126 of 5 stars$29.10+3.3%N/A+57.8%$408.20M$200K-2.75166Positive NewsAURAAura Biosciences1.386 of 5 stars$6.47-0.2%$22.00+240.0%-37.3%$402.54MN/A-3.3050ADCTADC Therapeutics2.1613 of 5 stars$3.51-0.8%$7.75+120.6%+6.5%$398.25M$70.84M-2.24310Positive NewsPRTCPureTech Health0.7251 of 5 stars$16.42+1.2%N/A-12.9%$391.71M$6.17M0.00100News CoverageShort Interest ↑ Related Companies and Tools Related Companies Solid Biosciences Competitors Astria Therapeutics Competitors Nanobiotix Competitors Fulcrum Therapeutics Competitors Cullinan Therapeutics Competitors Kamada Competitors Inhibrx Biosciences Competitors Aura Biosciences Competitors ADC Therapeutics Competitors PureTech Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRX) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
